The Novel Machine-learning-based Automatic Fly-behavioral Detection and Annotation system uses cameras and a newly developed software to track and identify complex interactive behaviors of individual flies within a larger group, allowing researchers to compare and contrast the behaviors of fruit flies with different genetic backgrounds.
Stefan C. Grant, MD, JD, MBA, will serve as the next Chief of the Section of Hematology and Medical Oncology in the John W. Deming Department of Medicine at Tulane University School of Medicine.
A. Oliver Sartor, MD, professor of medicine, medical director, Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research, Departments of Medicine and Urology, Tulane University, discusses emerging agents in prostate cancer.
An increasing amount of evidence shows that a proportion of patients with cancer found to have low-volume metastases at diagnosis see meaningful benefit from aggressive local therapy. Equally important, there have been no meaningful reductions in reported quality of life among patients receiving intensive local therapy, and a small percentage of patients appear to be cured with this strategy.
Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.
Research from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.
Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Prescott Deininger, PhD, Professor and Regents Distinguished Chair, director, Tulane Cancer Center, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, discusses how genetic instability plays a role in mutations that may lead to specific tumor types.
Roy Weiner, MD, Associate Dean for Clinical Research and Training Associate Director of Clinical Research for Tulane Cancer Center discusses the importance of racial and ethnic diversity in cancer research.